TY - JOUR
T1 - VEGF165, but not VEGF189, stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo
AU - Zhou, Zhichao
AU - Reddy, Krishna
AU - Guan, Hui
AU - Kleinerman, Eugenie S.
PY - 2007/11/1
Y1 - 2007/11/1
N2 - We previously showed that bone marrow stem cells participate in the tumor vessel expansion that supports the growth of Ewing's sarcoma tumors in vivo. The purpose of this study was to determine the relative importance of two isoforms of vascular endothelial growth factor (VEGF) in tumor vessel expansion and recruitment of bone marrow-derived cells during tumor growth. We injected VEGF165-siRNA-transfected cells (TCsi/7-1), control siRNA-transfected cells (TC/si-control), or TC71 parental Ewing's sarcoma cells into nude mice. The TCsi/7-1 tumors were then treated with adenoviral vectors expressing VEGF165 (Ad-VEGF165), VEGF189 (Ad-VEGF 189), or β-galactosidase (Ad-β-gal). Bone marrow cells labeled with fluorescent tracker dye were injected into the mice 3 weeks later. The TCsi/7-1 tumors were significantly smaller (P < 0.05), had decreased vessel density, and showed significantly lower bone marrow cell migration than did TC71 parental and TC/si-control tumors. Treatment with Ad-VEGF 165, but not Ad-VEGF189 or Ad-β-gal, resulted in a significant increase in bone marrow cell infiltration, tumor vessel density, and tumor growth. Immunohistochemical staining revealed that the injected bone marrow cells migrated to and incorporated into the expanding CD31+ tumor vessel network. Taken together, these data show that VEGF165 is a chemoattractant that recruits bone marrow cells into the tumor area. These data provide a mechanism by which Ewing's sarcoma cells induce vasculogenesis.
AB - We previously showed that bone marrow stem cells participate in the tumor vessel expansion that supports the growth of Ewing's sarcoma tumors in vivo. The purpose of this study was to determine the relative importance of two isoforms of vascular endothelial growth factor (VEGF) in tumor vessel expansion and recruitment of bone marrow-derived cells during tumor growth. We injected VEGF165-siRNA-transfected cells (TCsi/7-1), control siRNA-transfected cells (TC/si-control), or TC71 parental Ewing's sarcoma cells into nude mice. The TCsi/7-1 tumors were then treated with adenoviral vectors expressing VEGF165 (Ad-VEGF165), VEGF189 (Ad-VEGF 189), or β-galactosidase (Ad-β-gal). Bone marrow cells labeled with fluorescent tracker dye were injected into the mice 3 weeks later. The TCsi/7-1 tumors were significantly smaller (P < 0.05), had decreased vessel density, and showed significantly lower bone marrow cell migration than did TC71 parental and TC/si-control tumors. Treatment with Ad-VEGF 165, but not Ad-VEGF189 or Ad-β-gal, resulted in a significant increase in bone marrow cell infiltration, tumor vessel density, and tumor growth. Immunohistochemical staining revealed that the injected bone marrow cells migrated to and incorporated into the expanding CD31+ tumor vessel network. Taken together, these data show that VEGF165 is a chemoattractant that recruits bone marrow cells into the tumor area. These data provide a mechanism by which Ewing's sarcoma cells induce vasculogenesis.
UR - http://www.scopus.com/inward/record.url?scp=36248979685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36248979685&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-07-0174
DO - 10.1158/1541-7786.MCR-07-0174
M3 - Article
C2 - 18025258
AN - SCOPUS:36248979685
SN - 1541-7786
VL - 5
SP - 1125
EP - 1132
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 11
ER -